Conmed (CNMD) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall St rises as AI momentum holds heading into key earnings, Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- S&P Global explores potential separation of Capital IQ business
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- Equities end higher as Anthropic's IPO filing buoys AI stocks
CONMED (CNMD) PT Raised to $58 at Needham & Company Following 3Q Report
November 3, 2017 8:29 AM EDTNeedham & Company raised its price target on CONMED (NASDAQ: CNMD) to $58.00 (from $57.00) while maintaining a Buy rating following the company's 3Q release. Revenue was $190.1M vs. consensus of $187.1M and EPS was $0.42 vs. consensus of $0.41. lower than expected tax rate added ~$0.03 to... More



